Insider Transactions in Q1 2025 at Entrada Therapeutics, Inc. (TRDA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,929
-4.24%
|
$54,219
$11.68 P/Share
|
|
Mar 03
2025
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,566
-3.97%
|
$193,226
$11.68 P/Share
|
|
Mar 03
2025
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,138
-2.98%
|
$67,518
$11.68 P/Share
|
|
Mar 03
2025
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,144
-2.77%
|
$56,584
$11.68 P/Share
|
|
Mar 01
2025
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,400
+26.73%
|
-
|
|
Mar 01
2025
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,200
+20.82%
|
-
|
|
Mar 01
2025
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+22.81%
|
-
|
|
Mar 01
2025
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+24.64%
|
-
|